Oklo Inc.: The AI Power Trade Is Getting More Tangible

Oklo is still rated Buy, but the price target is cut from $99 to $88 due to dilution. On execution, Q2 2026 showed milestones including Groves achieving first criticality, Aurora-INL advancing, and Aurora-Ohio securing key agreements. The analyst modestly raises normalized EBITDA to $443 million, citing improved confidence in risk-adjusted capacity across Ohio, INL, Fuel, and Isotopes, though dilution remains a near-term headwind.

Analysis

OKLO is shifting from a pure science-vs-fantasy debate toward a capital-allocation story. In pre-commercial nuclear, the market usually pays for probability-weighted future cash flows, so execution milestones help—but dilution can matter more because every new equity check pushes the break-even terminal value farther out. The revised target is the tell: the upside case is still intact, but financing terms are now the dominant variable, not technical credibility.

The cleanest beneficiaries are the profitable nuclear-adjacent names that can monetize the buildout without needing repeated equity raises. BWXT stands out as the higher-quality way to own domestic nuclear momentum; fuel-cycle proxies like LEU also gain if the ecosystem keeps tightening around domestic sourcing and enriched fuel demand. By contrast, the rest of the pre-revenue nuclear cohort is vulnerable to basket de-rating if investors decide the industry-wide capital intensity is worse than modeled.

The contrarian miss is that milestone headlines can be mistaken for commercialization. The next 1-3 months matter more for financing structure, permitting cadence, and customer credit quality; the 6-18 month window is where the market will test whether these assets can clear a true cost-of-capital hurdle. What would falsify the constructive view is a large dilutive raise, licensing slippage, or weak evidence of project finance/offtake; what would force a higher valuation framework is non-dilutive capital or a strategic partner underwriting part of the rollout.

Key Decisions for Investors

• Favor BWXT over OKLO for nuclear exposure; consider a 3-6 month long BWXT / short OKLO pair to isolate real cash-flow generation from financing risk.
• Do not chase OKLO after execution headlines unless the company proves non-dilutive funding capacity; prefer to add only on a financing-related pullback or after a strategic capital commitment.
• If you want domestic fuel-cycle beta, use LEU as the cleaner expression and keep it paired against OKLO if the goal is to hedge dilution and execution uncertainty.
• Set a hard alert on any secondary offering or share-count increase >10% over the next 1-2 quarters; that would be the point where the market likely compresses the multiple again.
• Cover any short exposure immediately if OKLO secures project-finance-style capital or a credible utility/data-center offtake with customer funding attached; that would materially reduce the balance-sheet overhang.